Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States

BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Jara, Michele, Aquilina, Thomas, Aupperle, Peter, Rabinowicz, Adrian L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687626/
https://www.ncbi.nlm.nih.gov/pubmed/26719727
http://dx.doi.org/10.2147/DHPS.S97113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687626/
https://www.ncbi.nlm.nih.gov/pubmed/26719727
http://dx.doi.org/10.2147/DHPS.S97113

Ejemplares similares